Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination

As'ad E Bhorat, Shabir A Madhi, France Laudat, Vani Sundaraiyer, Alejandra Gurtman, Kathrin U Jansen, Daniel A Scott, Emilio A Emini, William C Gruber, Beate Schmoele-Thoma, As'ad E Bhorat, Shabir A Madhi, France Laudat, Vani Sundaraiyer, Alejandra Gurtman, Kathrin U Jansen, Daniel A Scott, Emilio A Emini, William C Gruber, Beate Schmoele-Thoma

Abstract

Objective: Immunocompromised individuals are at an increased risk of pneumococcal disease. Vaccination is recommended as an important strategy to reduce risk of pneumococcal disease in HIV-infected individuals. This study evaluated the safety and immunogenicity of three 13-valent pneumococcal conjugate vaccine (PCV13) doses followed by one dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) at 1-month intervals in pneumococcal vaccine-naive, HIV-infected individuals.

Design: This was a phase 3, open-label, single-arm study.

Methods: Pneumococcal vaccine-naive, HIV-infected individuals at least 6 years of age with CD4 T-cell count at least 200 cells/μl and viral load less than 50 000 copies/ml received three doses of PCV13 followed by one dose of PPSV23 at 1-month intervals. Serotype-specific antipneumococcal immune responses were assessed by IgG geometric mean concentrations (GMCs) and opsonophagocytic activity (OPA) assay geometric mean titres (GMTs) after each dose. Local reactions at the PCV13 injection site, systemic and other adverse events were collected.

Results: Three hundred and one individuals were enrolled and vaccinated; 279 completed the study. Statistically significant increases in IgG GMCs and OPA GMTs were observed for all serotypes after dose 1 of PCV13 compared with prevaccine levels. GMCs and GMTs were comparable or only modestly increased for all serotypes after PCV13 doses 2 and 3 and after PPSV23. The majority of local reactions and systemic events were mild to moderate in severity.

Conclusion: A three-dose regimen of PCV13 was well tolerated in pneumococcal vaccine-naive, HIV-infected individuals. Significant immune responses to all serotypes were observed following the first dose of PCV13, with only modest increases in antibody titres following subsequent PCV13 or PPSV23 administration.

Trial registration: ClinicalTrials.gov NCT00962780.

Figures

Fig. 1
Fig. 1
Antipneumococcal responses after PCV13 vaccination.

References

    1. Bliss SJ, O’Brien KL, Janoff EN, Cotton MF, Musoke P, Coovadia H, Levine OS. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis 2008; 8:67–80.
    1. Nunes MC, von Gottberg A, de Gouveia L, Cohen C, Kuwanda L, Karstaedt AS, et al. Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program. PLoS One 2011; 6:e27929.
    1. Nunes MC, von Gottberg A, de Gouveia L, Cohen C, Moore DP, Klugman KP, Madhi SA. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS 2011; 25:453–462.
    1. Everett DB, Mukaka M, Denis B, Gordon SB, Carrol ED, van Oosterhout JJ, et al. Ten years of surveillance for invasive Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi. PLoS One 2011; 6:e17765.
    1. Heffernan RT, Barrett NL, Gallagher KM, Hadler JL, Harrison LH, Reingold AL, et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005; 191:2038–2045.
    1. Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165:1533–1540.
    1. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816–819.
    1. Eramova I, Matic S, Munz M. HIV/AIDS treatment and care. Clinical protocols for the WHO European region. Copenhagen, Denmark: World Health Organization Europe; 2007.
    1. French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106–2111.
    1. Arpadi SM, Back S, O’Brien J, Janoff EN. Antibodies to pneumococcal capsular polysaccharides in children with human immunodeficiency virus infection given polyvalent pneumococcal vaccine. J Pediatr 1994; 125:77–79.
    1. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 1999; 18:524–530.
    1. Lopez-Palomo C, Martin-Zamorano M, Benitez E, Fernandez-Gutierrez C, Guerrero F, Rodriguez-Iglesias M, Giron-Gonzalez JA. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004; 72:517–524.
    1. Teshale EH, Hanson D, Flannery B, Phares C, Wolfe M, Schuchat A, Sullivan P. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998–2003. Vaccine 2008; 26:5830–5834.
    1. Nachman S, Kim S, King J, Abrams EJ, Margolis D, Petru A, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003; 112:66–73.
    1. Tarrago D, Casal J, Ruiz-Contreras J, Ramos JT, Rojo P, Snippe H, Jansen WT. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol 2005; 12:165–170.
    1. Feikin DR, Elie CM, Goetz MB, Lennox JL, Carlone GM, Romero-Steiner S, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001; 20:545–553.
    1. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812–822.
    1. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341–1348.
    1. Cornick JE, Everett DB, Broughton C, Denis BB, Banda DL, Carrol ED, Parry CM. Invasive Streptococcus pneumoniae in children, Malawi, 2004-2006. Emerg Infect Dis 2011; 17:1107–1109.
    1. von Gottberg A, Cohen C, de Gouveia L, Meiring S, Quan V, Whitelaw A, et al. Epidemiology of invasive pneumococcal disease in the preconjugate vaccine era: South Africa, 2003–2008. Vaccine 2013; 31:4200–4208.
    1. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz NM, de Man RA, van der Ende ME. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008; 197:292–294.
    1. Powis JE, Raboud J, Ostrowski M, Loutfy MR, Kovacs C, Walmsley SL. The recombinant hepatitis B surface antigen vaccine in persons with HIV: is seroconversion sufficient for long-term protection?. J Infect Dis 2012; 205:1534–1538.
    1. Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011; 29:7207–7211.
    1. Rabian C, Tschope I, Lesprit P, Katlama C, Molina JM, Meynard JL, et al. Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults. Clin Infect Dis 2010; 50:1174–1183.
    1. Lesprit P, Pedrono G, Molina JM, Goujard C, Girard PM, Sarrazin N, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21:2425–2434.
    1. Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine 2014; 32:2364–2374.
    1. Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on antipneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013; 31:3594–3602.
    1. Lu CL, Chang SY, Chuang YC, Liu WC, Su CT, Su YC, et al. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy. Vaccine 2014; 32:1031–1035.
    1. Tasker SA, Wallace MR, Rubins JB, Paxton WB, O’Brien J, Janoff EN. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002; 34:813–821.
    1. Chen M, Ssali F, Mulungi M, Awio P, Yoshimine H, Kuroki R, et al. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults. Vaccine 2008; 26:4962–4968.
    1. Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, Ganesan A, Patel S, Landrum ML, et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010; 202:1114–1125.
    1. Miiro G, Kayhty H, Watera C, Tolmie H, Whitworth JA, Gilks CF, French N. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005; 192:1801–1805.
    1. Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother 2012; 8:161–173.
    1. Sogaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, Davis HL, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010; 51:42–50.
    1. Glesby MJ, Watson W, Brinson C, Greenberg RN, Lalezari JP, Skiest D, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine. J Infect Dis 2014; doi: 10.1093/infdis/jiu631.
    1. de Roux A, Schmole-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46:1015–1023.
    1. Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205:1408–1416.
    1. Nair N, Moss WJ, Scott S, Mugala N, Ndhlovu ZM, Lilo K, et al. HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection. J Infect Dis 2009; 200:1031–1038.
    1. Frenck R, Jr, Thompson A, Senders S, Harris-Ford L, Sperling M, Patterson S, et al. 13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naive to 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2014; 33:183–189.
    1. National Health and Medical Research Council. The Australian Immunisation Handbook 10th edition 2013. Commonwealth of Australia. Canberra: (updated January 2014). 2013.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe